AI Article Synopsis
Article Abstract
Objectives: To compare the clinical and radiological effectiveness of ocrelizumab in primary progressive multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS) in a clinical practice setting and describe its tolerability and adverse events.
Methods: A retrospective observational cohort study was conducted comparing clinical and magnetic resonance imaging (MRI) data of all patients with (pw)PPMS and RRMS who had received treatment with ocrelizumab at least one cycle and have been followed up for one year at minimum.
Results: 42 patients (27 women) treated with ocrelizumab: 29 had RRMS and 13 PPMS. The follow-up period was 26.4 ± 8.4 months. The proportion of pwRRMS with no evidence of disease activity (NEDA) in the first year was 69.2% and in the second was 80%. In the first year, radiological activity was reduced by 80.0% in pwRRMS and 91.7% in pwPPMS. In the second year, radiological activity was completely reduced in both groups. A statistically significant difference (p<0.05) was observed between the pre-ocrelizumab rate of disability progression vs. the first year rate of progression for pwRRMS and pwPPMS. However, an increase in the disability progression rate in the second year of treatment was found in pwPPMS. Ocrelizumab was mostly well tolerated and some adverse effects were reported: infusion-related reactions (IRRs) were the most frequent adverse event, followed by infections and hematological side effects. Discontinuations were due to infections, hematological complications, and perception of ineffectiveness.
Conclusions: Ocrelizumab was very effective in reducing relapses and MRI activity. The rate of progression was slowed down; however, the effect was more evident for pwRRMS than for pwPPMS over time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2022.104441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrated Transcriptome Analysis Reveals Molecular Subtypes and ceRNA Networks in Multiple Sclerosis.
Degener Neurol Neuromuscul Dis
December 2024
Department of Clinical Laboratory, Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, Jiangsu, 214504, People's Republic of China.
Aim: Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS). While extensively studied, its molecular subtypes and mechanisms remain poorly understood, hindering the identification of effective therapeutic targets.
Methods: We used ConsensusClusterPlus to analyze transcriptome data from 215 MS patient samples, identifying distinct molecular subtypes.
Autoinjectors for Administering Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis in Europe: A Survey of Patient and Nurse Preferences.
Degener Neurol Neuromuscul Dis
December 2024
Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, Germany.
Purpose: Multiple sclerosis (MS) is a neurological disorder affecting almost 2.8 million people globally, approximately 80-85% of whom have the relapsing-remitting form of the disease (RRMS). There are several autoinjectors available for the administration of injectable disease-modifying therapies for the treatment of MS.
View Article and Find Full Text PDFExploring sleep-related disorders in patients with multiple sclerosis: A questionnaire-based approach.
J Family Med Prim Care
November 2024
Department of Neurology, King Fahad General Hospital, Jeddah, Saudi Arabia.
Background: Multiple sclerosis (MS) is considered the most prevalent neurological disorder in young adults with many patients manifesting sleep-related disorders (SRD) due to its pathomechanisms. This is subsequently reflected in patients' quality of life and physical activities.
Material And Methods: This is a cross-sectional study at a tertiary care center.
Cranial volume measurement with artificial intelligence and cognitive scales in patients with clinically isolated syndrome.
Front Neurol
December 2024
Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Istanbul, Türkiye.
Objective: We aimed to investigate the relationship between volumetric measurements of specific brain regions which were measured with artificial intelligence (AI) and various neuropsychological tests in patients with clinically isolated syndrome.
Materials And Methods: A total of 28 patients diagnosed with CIS were included in the study. The patients were administered Öktem Verbal Memory Processes Test, Symbol Digit Modalities Test (SDMT), Backward-Forward Digit Span Test, Stroop Test, Trail Making Test, Controlled Oral Word Association Test (COWAT), Brief Visuospatial Memory Test, Judgement of Line Orientation Test, Beck Depression Scale, Beck Anxiety Scale and Fatigue Severity Scale.
Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study.
Eur J Neurol
January 2025
Multiple Sclerosis Center, Binaghi Hospital, Cagliari, Italy.
Background: The study aims to examine the age and disability levels at diagnosis in people with multiple sclerosis (PwMS), with and without autoimmune comorbidities (AC), and the effect of AC on NEDA-3 status and to characterize AC associated with MS, comparing also therapeutic approaches between MS patients with and without other AC.
Methods: This population-based, multicentric study enrolled patients with relapsing-remitting MS (RRMS) with AC (AC group) or without AC (reference group) from 14 MS centers. Demographical, clinical features, treatment information, MRI activity, EDSS, and no evidence of disease activity (NEDA-3) status were assessed at T36 (enrollment time) and T0 (36 months prior).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!